Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stada And Alvotech Eye Potential EU Ustekinumab Nod This Year

A Frontrunner Filing For A Stelara Biosimilar Has Been Accepted For Review By The EMA

Executive Summary

Alvotech and Stada have indicated that they could receive an EMA opinion on their AVT04 Stelara biosimilar as early as the second half of 2023, after the agency confirmed acceptance of their ustekinumab filing.

You may also be interested in...

Alvotech And Stada Scoop First EU Stelara Biosimilar

Stada and Alvotech’s Uzpruvo ustekinumab biosimilar is set to become the EU’s first approved rival to Stelara after the EMA’s CHMP issued a positive opinion for the product. Meanwhile, the committee also endorsed a Lucentis biosimilar from Qilu Pharma as well as azacitidine and paclitaxel generics from Fresenius Kabi and Accord.

Alvotech Receives CRL From FDA Over Ustekinumab Filing

Alvotech has announced that, “as expected”, its US filing for its AVT04 ustekinumab candidate has resulted in a complete response letter from the FDA over manufacturing facility deficiencies, following similar knockbacks for its adalimumab biosimilar. However, the firm anticipates an inspection and a new goal date for the proposed Stelara rival long before its planned February 2025 launch date.

Accord Files Stelara Rival With EMA

Intas has announced that its Accord Healthcare unit has filed in Europe the DMB-3115 biosimilar ustekinumab candidate licensed from Japan’s Meiji Seika Pharma and Korea’s Dong-A.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts